|Videos|July 16, 2020
Glaucoma 360: Pharmaceuticals in the glaucoma industry
Author(s)Alex Delaney-Gesing
ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting.
Advertisement
ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses the takeaways from a panel discussion on the progression of glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting in San Francisco, California.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approvals in 2025: What changed and why it matters for ophthalmologists
2
Achieving a new level of refractive precision: Surgical strategies
3
What changed in glaucoma care in 2025: Surgeon perspective
4
Global trial equity: How LMIC data is reshaping US ophthalmology research
5